Rosetta Genomics (ROSGQ) 6-K 10 Oct 17 2017 Q2 Exhibit 6-K Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2017
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Entity Registrant Name	Rosetta Genomics Ltd.
Entity Central Index Key	1,362,959
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Entity Filer Category	Non-accelerated Filer

CONDENSED INTERIM CONSOLIDATED

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 1,325	$ 4,593
Short-term bank deposits and restricted cash	58	52
Trade receivables	472	331
Other accounts receivable and prepaid expenses	515	291
Current assets related to discontinued operations	3,310	4,246
Total current assets	5,680	9,513
LONG TERM ASSETS:
Property and equipment, net	522	625
Long-term bank deposits and other long-term receivables	5	6
Long term assets related to discontinues operations	0	1,817
Total long-term assets	527	2,448
Total assets	6,207	11,961
CURRENT LIABILITIES:
Current maturity of long-term capital lease	55	55
Trade payables	1,036	872
Other accounts payable and accruals	965	2,003
Current liabilities related to discontinued operations	658	874
Total current liabilities	2,714	3,804
LONG-TERM LIABILITIES:
Debentures and Warrants	2,357	3,675
Long term capital lease obligations	37	65
Total long-term liabilities	2,394	3,740
COMMITMENTS AND CONTINGENT LIABILITIES
SHAREHOLDERS EQUITY:
Ordinary Shares of NIS 7.2 par value: 5,000,000 shares authorized at June 30, 2017 and December 31, 2016; 2,588,086 (unaudited) and 1,842,704 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	4,904	3,442
Additional paid-in capital	157,285	157,478
Accumulated deficit	(161,090)	(156,503)
Total shareholders’ equity	1,099	4,417
Total liabilities and shareholders’ equity	$ 6,207	$ 11,961

CONDENSED INTERIM CONSOLIDATED3

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - ₪ / shares	Jun. 30, 2017	Dec. 31, 2016
Ordinary shares, par value per share	₪ 7.2	₪ 7.2
Ordinary shares, shares authorized	5,000,000	5,000,000
Ordinary shares, shares issued	2,588,086	1,842,704
Ordinary shares, shares outstanding	2,588,086	1,842,704

CONDENSED INTERIM CONSOLIDATED4

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues	$ 870	$ 404	$ 1,608	$ 788
Cost of revenues	569	496	1,099	743
Gross profit (loss)	301	(92)	509	45
Operating expenses:
Research and development, net	476	617	1,191	1,459
Sales, marketing and business development	521	1,153	1,916	2,395
General and administrative	675	1,392	1,930	2,760
Total operating expenses	1,672	3,162	5,037	6,614
Operating loss	1,371	3,254	4,528	6,569
Financial expenses (income), net	(229)	0	(1,624)	24
Income tax expenses	0	6	0	12
Net comprehensive loss from continuing operations	1,142	3,260	2,904	6,605
Net comprehensive loss from discontinued operations	929	133	1,683	825
Net comprehensive loss	$ 2,071	$ 3,393	$ 4,587	$ 7,430
Basic and diluted net loss per ordinary share attributable to Rosetta Genomics’ shareholders from continuing operations	$ 0.45	$ 1.87	$ 1.31	$ 3.82
Basic and diluted net loss per ordinary share attributable to Rosetta Genomics’ shareholders from discontinued operations	0.36	0.08	0.76	0.48
Basic and diluted net loss	$ 0.81	$ 1.95	$ 2.07	$ 4.30
Weighted average number of ordinary shares used to compute basic and diluted net loss per ordinary share	2,545,926	1,738,549	2,224,951	1,729,705

CONDENSED INTERIM CONSOLIDATED5

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Share capital [Member]	Additional paid-in capital [Member]	Accumulated deficit [Member]
Balance at Dec. 31, 2015	$ 19,620	$ 3,194	$ 156,696	$ (140,270)
Balance, shares at Dec. 31, 2015		1,709,628
Exercise of warrants	0	$ 51	(51)	0
Exercise of warrants, shares		27,777
Share-based compensation related to options and RSUs issued to employees and directors	459	$ 2	457	0
Share-based compensation related to options and RSUs issued to employees and directors,shares		1,394
Net loss	(7,430)	$ 0	0	(7,430)
Balance at Jun. 30, 2016	12,649	$ 3,247	157,102	(147,700)
Balance, shares at Jun. 30, 2016		1,738,799
Balance at Dec. 31, 2016	$ 4,417	$ 3,442	157,478	(156,503)
Balance, shares at Dec. 31, 2016	1,842,704	1,842,704
Conversion of debenture	$ 873	$ 1,461	(588)	0
Conversion of debenture, shares		742,244
Share-based compensation related to options and RSUs issued to employees and directors	396	$ 1	395	0
Share-based compensation related to options and RSUs issued to employees and directors,shares		417
Share rounding related to March 2017 reverse stock split		2,721
Net loss	(4,587)	$ 0	0	(4,587)
Balance at Jun. 30, 2017	$ 1,099	$ 4,904	$ 157,285	$ (161,090)
Balance, shares at Jun. 30, 2017	2,588,086	2,588,086

CONDENSED INTERIM CONSOLIDATED6

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (4,587)	$ (7,430)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	117	144
Decrease (increase) in trade receivables	(141)	23
Decrease (increase) in other accounts receivable and prepaid expenses	(224)	1,527
Stock-based compensation	396	459
Revaluation losses (gain) of Debentures and Warrants related to share purchase agreements	(1,738)	0
Increase in trade payables	164	8
Increase (decrease) in other accounts payable and accruals	(1,038)	306
Net cash used in operating activities from continuing operations	(7,051)	(4,963)
Cash flows from investing activities:
Purchase of property and equipment	(14)	(79)
Investment in (proceeds from) bank deposits and restricted cash	(5)	492
Net cash provided by (used in) investing activities from continuing operations	(19)	413
Cash flows from financing activities:
Issuance of Debentures, net	1,292	0
Repayment of capital lease	(28)	0
Net cash provided by financing activities from continuing operations	1,264	0
Net cash provided by (used in) operating activities from discontinued operations	1,332	333
Net cash provided by (used in) investing activities from discontinued operations	81	(175)
Net cash provided by (used in) financing activities from discontinued operations	0	0
Decrease in cash and cash equivalents	(4,393)	(4,392)
Cash and cash equivalents at beginning of period	6,163	12,447
Cash and cash equivalents at end of period	1,770	8,055
Less cash and cash equivalents of discontinued operation at the end of the period	445	234
Cash and Cash Equivalents, at Carrying Value	1,325	7,821
Supplemental disclosure of non-cash activities:
Purchase of property and equipment under capital lease	0	147
Conversion of Debenture to shares	$ 872	$ 0

GENERAL

GENERAL	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	GENERAL Organization and Business Rosetta Genomics Ltd. (the “Company”) commenced operations on March 9, 2000. The Company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The Company’s microRNA-based tests, RosettaGX Cancer Origin™, RosettaGX Reveal™, mi-LUNG™, and mi-KIDNEY™, are commercially available worldwide and all samples are processed in its Philadelphia-based CAP-accredited, Clinical Laboratories Improvement Amendments (“CLIA”) certified lab. The Company’s broad menu of molecular and other assays for bladder, lung, prostate and breast cancer patients are offered through its facility in Lake Forest, California. The Company has three wholly-owned subsidiaries in the United States: (1) Rosetta Genomics, Inc. (“Rosetta Inc.”), (2) Minuet Diagnostics, Inc. (“Minuet”), and (3) CynoGen, Inc. (“CynoGen” or “PersonalizeDx” and collectively with Rosetta Inc. and Minuet, the “U.S. Subsidiaries”). The principal business activities of the U.S. Subsidiaries are to commercialize the Company’s products, perform tests in its CLIA-approved laboratories and expand the business of the Company in the United States. Discontinued Operations During the first half of 2017, the Company committed to a plan to sell its PersonalizeDx business in order to focus on its core business. Accordingly, PersonalizeDx’s results of operations and statement of financial position balances are presented as discontinued operations. All prior periods’ comparable results of operation, assets and liabilities have been retroactively reclassified to present the discontinued operations. Six months ended 2017 2016 Revenues $ 2,741 $ 4,227 Cost of revenues 2,167 2,904 Operating expenses 2,256 2,148 Operating loss 1,682 825 Financial expenses, net 1 - Net loss $ 1,683 $ 825 Depreciation expense totaled $ 276 314 The major classes of assets and liabilities that were classified as discontinued operations were as follows: June 30 December 31 2017 2016 Cash and cash equivalents $ 445 $ 1,570 Short-term bank deposits - 78 Trade receivables 2,018 2,520 Other accounts receivable and prepaid expenses 68 78 Property and equipment, net 779 1,817 Total assets of discontinued operations $ 3,310 $ 6,063 Trade payables 515 702 Accrued expenses and other liabilities 143 172 Total liabilities of discontinued operations $ 658 $ 874 On September 8, 2017, subsequent to the balance sheet date, the Company entered into a definitive agreement to sell the stock of Minuet along with its PersonalizeDx business to Pragmin Prognosis, Inc., in order to focus on its core miRNA business. The transaction is subject to certain closing conditions. As of the date of this filing, this transaction has not yet closed. Reverse Stock Split On March 16, 2017, the shareholders of the Company, at an Extraordinary General Meeting of Shareholders, approved a reverse stock split and consolidation of the registered (authorized) share capital of the Company as follows: every twelve (12) Ordinary Shares with a nominal (par) value of NIS 0.6 each were consolidated into one (1) Ordinary Share with a nominal (par) value of NIS 7.2 each. Liquidity and Capital Resources During the six-month period ended June 30, 2017, and the year ended December 31, 2016, the Company incurred operating losses from continued operation amounting to $ 2,904 13,184 As of June 30, 2017, the Company’s cash position (cash and cash equivalents and short-term bank deposits) totaled approximately $ 1,325 On August 3, 2017, the Company entered into a securities purchase agreement with certain institutional healthcare investors in connection with the offering of 138,000 7.2 1,811,974 1.40 1.39 2,712 The aggregate net proceeds to the Company from the Offering, after deducting the placement agent’s fees and expenses and the Company’s estimated offering expenses were approximately $ 2,200 The Series A Warrants are immediately exercisable upon issuance and have a term of five years and the Series B Warrants are immediately exercisable upon issuance until exercised in full. The exercise price of the Series A Warrants is $ 1.50 0.01 On September 28, 2017, the Company entered into definitive agreements with one prominent institutional healthcare investor for a private placement of unregistered convertible debentures (convertible into 2,173,914 2,173,914 2,000 The convertible debentures will (i) have a term of 30 0.92 The warrants will (i) have a term of five years, (ii) be exercisable upon issuance and (iii) have an exercise price of $ 1.15 In the event of a reverse stock split, the conversion price of the convertible debentures may be reduced to the average of the volume weighted average price for the two days with the lowest volume weighted average price during the ten trading days immediately following the reverse stock split; provided that the conversion price of the debentures will not be adjusted below $0.20 per share. Additionally, the conversion price of the convertible debentures are subject to full ratchet anti-dilution protection in the event the Company issues securities below the conversion price then in effect; provided that the conversion price of the debentures will not be adjusted below $ 0.20 According to management estimates, liquidity resources as of June 30, 2017, and net proceeds from the August 2017 and September 2017 offerings, will be sufficient to maintain the Company’s operations into the latter part of the fourth quarter of 2017. The Company’s inability to raise funds to carry out its business plan will have a severe negative impact on its ability to remain a viable company. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The unaudited condensed interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets or liabilities that might be necessary should the Company be unable to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2017
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2: SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2016, are applied consistently in these financial statements. For further information, refer to the consolidated financial statements for the year ended December 31, 2016, set forth in the Company’s Annual Report on Form 20-F as filed with the U.S. Securities and Exchange Commission on March 30, 2017, except for the following: Recently Adopted Accounting Pronouncements: In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2016-09, “Compensation - Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 permits entities to make an accounting policy election related to how forfeitures will impact the recognition of compensation cost for stock-based compensation: to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures as they occur. Upon adoption of ASU 2016-09, the Company elected to keep its current accounting policy to estimate the total number of awards for which the requisite service period will not be rendered. Accordingly, the guidance did not have a material impact on the Company’s consolidated financial results. I n May 2014, the FASB issued ASU 2014-09, “Revenue from Contract with Customers”, which introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. Numerous updates were issued in 2016 that provide clarification on a number of specific issues as well as requiring additional disclosures. The new standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. While the Company has not yet completed its final review of the impact of the new standard, the Company does not currently anticipate a material impact on its revenue recognition practices. The Company is still evaluating disclosure requirements under the new standard and will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company’s current conclusions. The Company expects to adopt the new standard using the modified retrospective method starting January 1, 2018. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting, which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. The standard is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adoption of this standard on its consolidated financial statements. In July 2017, the FASB issued ASU No. 2017-11. ASU 2017-11 - Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU was issued to address the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. The ASU, among other things, eliminates the need to consider the effects of down round features when analyzing convertible debt, warrants and other financing instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The amendments are effective for fiscal years beginning after December 15, 2018, and should be applied retrospectively. Early adoption is permitted, including adoption in an interim period. The Company plans to adopt ASU 2017-11 in the first quarter of the Company’s fiscal year 2018. The Company does not expect the adoption of ASU 2017-11 will have a material impact on its consolidated financial statements and related disclosures.

UNAUDITED INTERIM CONSOLIDATED

UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS	6 Months Ended
	Jun. 30, 2017
Unaudited Interim Consolidated Financial Statements [Abstract]
UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS	UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six-month period ended June 30, 2017, are not necessarily indicative of the results that may be expected for the year ended December 31, 2017.

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	6 Months Ended
	Jun. 30, 2017
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENT	FAIR VALUE MEASUREMENT The Company applies ASC 820, “Fair Value Measurements and Disclosures”. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows: Level 1 Level 2 Level 3 The availability of observable inputs can vary from investment to investment and is affected by a wide variety of factors, including, for example, the type of investment, the liquidity of markets and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment and the investments are categorized as Level 3. The following methods and assumptions were used by the Company and its subsidiaries in estimating their fair value disclosures for financial instruments: The carrying amounts of cash and cash equivalents, short-term bank deposits, trade receivables, trade payables, and other accounts payable approximate their fair values due to the short-term maturities of such instruments. The Company measures its Debentures and Warrants at fair value each reporting period until they are exercised or expired, with changes in the fair values being recognized in the Company’s statement of comprehensive loss as financial income or expense, as applicable (see Note 5). The Company uses numerous iteration of option pricing model (Black-Scholes-Merton) to determine the fair value of these Debentures and Warrants. Significant inputs included an estimate of the fair value of the Company’s Ordinary Shares as of June 30, 2017, the remaining contractual life of the warrants, a risk-free interest rate, and an estimate of the Company’s share expected volatility. The fair value of the Debentures and Warrants classified within Level 3. The fair value of the Debentures and Warrants at June 30, 2017 was $ 2,357 1,737 Fair value measurements Level 1 Level 2 Level 3 Liabilities: Debentures and Warrants - - $ 2,357 Total Financial liabilities - - $ 2,357 Total fair value as of January 1, 2017 $ 3,675 Issuance of PIPE Debentures 1,292 Conversion of Debentures (873) Gain from revaluation of Debentures and Warrants (1,737) Total fair value as of June 30, 2017 $ 2,357

DEBENTURES AND WARRANTS

DEBENTURES AND WARRANTS	6 Months Ended
	Jun. 30, 2017
Warrants and Debentures Disclosure [Abstract]
DEBENTURES AND WARRANTS	NOTE 5: DEBENTURES AND WARRANTS On November 23, 2016, the Company entered into a securities purchase agreement with a prominent institutional healthcare investor to purchase (i) an aggregate of 91,250 6.00 3,160 833,334 10.20 1,293 3,708 1,292 The Debentures are non-interest bearing, have a term of 30 6.00 3.0544 The 2016 Warrants were immediately exercisable upon issuance and have a term of five years. The initially exercise price of the 2016 Warrants was $ 10.2 June 30, 2017 Risk-free interest rate 1.16%-1. 72 % Expected volatility 82.98%-83.02 % Expected life (in years) 0.63-4.42 Expected dividend yield 0 % Fair value: Warrants $ 1,682 June 30, 2017 Risk-free interest rate 1.16 % Expected volatility 88.41 % Expected life (in years) 0.42 Expected dividend yield 0 % Fair value: Debentures $ 675 The Company accounted for the Debentures according to the provisions of ASC 815 and for the Warrants according to the provisions of ASC 480 and based on terms of the Debentures and the warrants classified them as liabilities. The Company elected to measure the Debentures and Warrants under the fair value option in accordance with ASC 815. Under the fair value option both the Debentures and Warrants will be measured at fair value in each reporting period until they will be converted, exercised or expired, with changes in the fair values being recognized in the Company’s consolidated statement of comprehensive loss as financial income or expense. In accordance with ASC 815, the proceeds received for the issuance of the Debentures and Warrants were allocated at fair value conducted on an arm’s-length basis. As of June 30, 2017, the Company re-measured the Warrants in the amount of $ 1,682 675 1,737 From January 1, 2017, through June 30, 2017, $2,427 principal amount of the Debentures were converted into of 742,244 Ordinary Shares of the Company. In July and August 2017, subsequent to the balance sheet date, an additional $457 principal amount of the Debentures were converted into of 266,227 Ordinary Shares of the Company.

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	6 Months Ended
	Jun. 30, 2017
COMMITMENTS AND CONTINGENT LIABILITIES [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 6: COMMITMENTS AND CONTINGENT LIABILITIES a. Restricted cash and restricted bank deposit: As of June 30, 2017, restricted cash was primarily attributed to bank guarantees to the landlords of the Company’s in the amount of approximately $ 58 b. The facilities of the Company and its U.S. subsidiaries are leased under various operating lease agreements, the latest of which ends in 2018. Aggregate future minimum lease commitments under the non-cancelable operating lease agreements as of June 30, 2017, are as follows: 2017 $ 184 2018 283 Total $ 467 Lease expenses from continuing operation for the Company’s facilities for the six months ended June 30, 2017 and 2016, were $ 218 204 c. The Company leases its motor vehicles under cancelable operating lease agreements. The minimum payment under these operating leases, upon cancellation of these lease agreements was $ 5 L ease expenses for motor vehicles for the six months ended June 30, 2017 and 2016, were $ 18 20 d. The Company entered into a three-year capital lease agreement in which it purchased lab equipment for its operation. 2017 $ 28 2018 55 2019 14 Total lease payments $ 97 e. In May 2006, the Company signed a royalty-bearing, co-exclusive, worldwide license agreement with a third party. Under this agreement, the Company was granted the right to make, use and sell the third party’s proprietary microRNAs for diagnostic purposes including a limited right to sublicense. In consideration for this license the Company paid an initiation fee and will pay a fixed annual license maintenance fee, royalties based on net sales and a percentage of the Company’s revenues from any sublicense. The Company estimates that until 2029 the minimum aggregate license maintenance fees over the term of this agreement should be approximately $ 960 500 f. In June 2006, the Company signed a royalty-bearing, co-exclusive, worldwide license agreement with a third party. Under this agreement, the Company licensed from this third party the rights to its proprietary microRNAs for diagnostic purposes. In consideration for this license the Company paid an initiation fee and will pay a fixed annual license maintenance fee, royalties based on net sales and a percentage of the Company’s revenue from any sublicense. The Company estimates that until 2022 the minimum aggregate license maintenance fees over the term of this agreement should be approximately $ 445 188 g. In August 2006, the Company signed a royalty-bearing, exclusive, worldwide license agreement with a third party. Under this agreement, the Company has exclusively licensed from this third party the rights to its proprietary microRNAs for all fields and applications including a limited right to sublicense. In consideration for this license the Company paid an initiation fee and will pay minimum annual royalties, royalties based on net sales and a percentage of the Company’s revenues from any sublicense. This agreement was amended and restated in August 2011 and is now on a non-exclusive basis. For the amendment, the Company paid an amendment fee. The Company estimates that until 2032 the aggregate minimum royalties over the term of this agreement should be approximately $ 320 155 h. In December 2006, the Company signed a royalty-bearing, non-exclusive, worldwide license agreement with a third party. Under this agreement the Company licensed from the third party its proprietary microRNAs for research purposes. In consideration for this license the Company paid an initiation fee and will pay a fixed annual license maintenance fee, royalties based on net sales and a percentage of the Company’s revenues from any sublicenses. The Company estimates that until 2022 the minimum aggregate license maintenance fees over the term of this agreement should be approximately $ 274 94 i. In May 2007, the Company signed a royalty-bearing, co-exclusive, worldwide license agreement with a third party. Under this agreement, the Company has licensed from this third party the rights to its proprietary microRNAs for therapeutic purposes including a limited right to sublicense. In consideration for this license the Company paid an initiation fee and will pay a fixed annual license maintenance fee, payments based on milestones and royalties based on net sales and a percentage of the Company’s revenues from any sublicense. The Company estimates that until 2029 the minimum aggregate maintenance fees over the term of this agreement should be approximately $ 690 375 j. In January 2008, the Company signed a royalty-bearing, co-exclusive, worldwide license agreement with a third party. Under this agreement, the Company was granted the right to make, use and sell the third party’s proprietary microRNAs for research purposes including a limited right to sublicense. In consideration for this license the Company paid an initiation fee and will pay a fixed annual license maintenance fee, royalties based on net sales and a percentage of the Company’s revenues from any sublicense. The Company estimates that until 2029 the minimum aggregate license maintenance fees over the term of this agreement should be approximately $ 440 250

SHARE CAPITAL

SHARE CAPITAL	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
SHARE CAPITAL	NOTE 6: SHARE CAPITAL a. Stock-based compensation During the six-month period ended June 30, 2017, the Company’s Board of Directors granted employees options to purchase 19,793 0.48 0.56 The Company estimates the fair value of stock options granted during the six-month period ended June 30, 2017, under ASC 718 using the Black-Scholes option pricing model with the following weighted-average assumptions: expected volatility of 1.14 2.17 2.33 0 6 6.25 10 During the six month periods ended June 30, 2017 and 2016, the Company recorded stock-based compensation in a total amount of $ 396 459 b. Warrants For the six months ended June 30, 2017, no warrants were exercised and 2,364 1,019,228

FINANCIAL INCOME, NET

FINANCIAL INCOME, NET	6 Months Ended
	Jun. 30, 2017
FINANCIAL EXPENSE (INCOME), NET [Abstract]
FINANCIAL INCOME, NET	NOTE 7: FINANCIAL INCOME, NET Six months ended, 2017 2016 Unaudited Financial income: Revaluation of Debentures and warrants related to share purchase agreement $ 1,737 $ - Foreign currency adjustments gains, net 15 - Total financial income 1,752 - Financial expenses: Foreign currency adjustments losses, net - 9 Bank commissions 38 15 Issuance expenses of Debentures and Warrants classified as liabilities 90 - Total financial expenses 128 24 Total financial expense (income), net $ (1,624) $ 24

SIGNIFICANT ACCOUNTING POLICI15

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2017
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements: In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2016-09, “Compensation - Stock Compensation (Topic 718)” (“ASU 2016-09”). ASU 2016-09 permits entities to make an accounting policy election related to how forfeitures will impact the recognition of compensation cost for stock-based compensation: to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures as they occur. Upon adoption of ASU 2016-09, the Company elected to keep its current accounting policy to estimate the total number of awards for which the requisite service period will not be rendered. Accordingly, the guidance did not have a material impact on the Company’s consolidated financial results. I n May 2014, the FASB issued ASU 2014-09, “Revenue from Contract with Customers”, which introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. Numerous updates were issued in 2016 that provide clarification on a number of specific issues as well as requiring additional disclosures. The new standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. While the Company has not yet completed its final review of the impact of the new standard, the Company does not currently anticipate a material impact on its revenue recognition practices. The Company is still evaluating disclosure requirements under the new standard and will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company’s current conclusions. The Company expects to adopt the new standard using the modified retrospective method starting January 1, 2018. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation: Scope of Modification Accounting, which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. The standard is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adoption of this standard on its consolidated financial statements. In July 2017, the FASB issued ASU No. 2017-11. ASU 2017-11 - Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU was issued to address the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. The ASU, among other things, eliminates the need to consider the effects of down round features when analyzing convertible debt, warrants and other financing instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The amendments are effective for fiscal years beginning after December 15, 2018, and should be applied retrospectively. Early adoption is permitted, including adoption in an interim period. The Company plans to adopt ASU 2017-11 in the first quarter of the Company’s fiscal year 2018. The Company does not expect the adoption of ASU 2017-11 will have a material impact on its consolidated financial statements and related disclosures.

GENERAL (Tables)

GENERAL (Tables)	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of the Discontinued Operations	The results of the discontinued operations, including prior periods’ comparable results, assets and liabilities, which have been retroactively included in discontinued operations as separate line items in the statements of comprehensive loss and balance sheets, are presented below: Six months ended 2017 2016 Revenues $ 2,741 $ 4,227 Cost of revenues 2,167 2,904 Operating expenses 2,256 2,148 Operating loss 1,682 825 Financial expenses, net 1 - Net loss $ 1,683 $ 825 June 30 December 31 2017 2016 Cash and cash equivalents $ 445 $ 1,570 Short-term bank deposits - 78 Trade receivables 2,018 2,520 Other accounts receivable and prepaid expenses 68 78 Property and equipment, net 779 1,817 Total assets of discontinued operations $ 3,310 $ 6,063 Trade payables 515 702 Accrued expenses and other liabilities 143 172 Total liabilities of discontinued operations $ 658 $ 874

FAIR VALUE MEASUREMENT (Tables)

FAIR VALUE MEASUREMENT (Tables)	6 Months Ended
	Jun. 30, 2017
FAIR VALUE MEASUREMENTS [Abstract]
Schedule Of Present Liabilities Balances Measured At Fair Value On A Recurring Basis	The following table present liabilities balances measured at fair value on a recurring basis as of June 30, 2017: Fair value measurements Level 1 Level 2 Level 3 Liabilities: Debentures and Warrants - - $ 2,357 Total Financial liabilities - - $ 2,357
Schedule Of Changes In The Company’s Liabilities Measured At Fair Value	The following table summarizes the changes in the Company’s liabilities measured at fair value (Level 3), during the six months period ended June 30, 2017: Total fair value as of January 1, 2017 $ 3,675 Issuance of PIPE Debentures 1,292 Conversion of Debentures (873) Gain from revaluation of Debentures and Warrants (1,737) Total fair value as of June 30, 2017 $ 2,357

DEBENTURES AND WARRANTS (Tables

DEBENTURES AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2017
Debenture [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of the Debentures was measured using iterations of the Black-Scholes-Merton model. In estimating the Debentures’ fair value, the Company used the following assumptions: June 30, 2017 Risk-free interest rate 1.16 % Expected volatility 88.41 % Expected life (in years) 0.42 Expected dividend yield 0 % Fair value: Debentures $ 675
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of the Warrants was measured using iterations of the Black-Scholes-Merton model. In estimating the Warrants’ fair value, the Company used the following assumptions: June 30, 2017 Risk-free interest rate 1.16%-1. 72 % Expected volatility 82.98%-83.02 % Expected life (in years) 0.63-4.42 Expected dividend yield 0 % Fair value: Warrants $ 1,682

COMMITMENTS AND CONTINGENT LI19

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	6 Months Ended
	Jun. 30, 2017
COMMITMENTS AND CONTINGENT LIABILITIES [Abstract]
Aggregate Minimum Rental Commitments Under the Non-Cancelable Rent Agreements	2017 $ 184 2018 283 Total $ 467
Schedule of Future Minimum Lease Payments for Capital Leases	The following table is a schedule, by years, of the future minimum lease payments required as of June 30, 2017: 2017 $ 28 2018 55 2019 14 Total lease payments $ 97

FINANCIAL INCOME, NET (Tables)

FINANCIAL INCOME, NET (Tables)	6 Months Ended
	Jun. 30, 2017
FINANCIAL EXPENSE (INCOME), NET [Abstract]
Schedule of Financial Loss (Income)	Six months ended, 2017 2016 Unaudited Financial income: Revaluation of Debentures and warrants related to share purchase agreement $ 1,737 $ - Foreign currency adjustments gains, net 15 - Total financial income 1,752 - Financial expenses: Foreign currency adjustments losses, net - 9 Bank commissions 38 15 Issuance expenses of Debentures and Warrants classified as liabilities 90 - Total financial expenses 128 24 Total financial expense (income), net $ (1,624) $ 24

GENERAL (discontinued operation

GENERAL (discontinued operations) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues			$ 2,741	$ 4,227
Cost of revenues			2,167	2,904
Operating expenses			2,256	2,148
Operating loss			1,682	825
Financial expenses, net			1	0
Net loss	$ 929	$ 133	1,683	825
Depreciation expense			$ 276	$ 314

GENERAL (schedule of assets and

GENERAL (schedule of assets and liabilities classified as discontinued operations) (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016
Cash and cash equivalents	$ 445	$ 1,570	$ 234
Short-term bank deposits	0	78
Trade receivables	2,018	2,520
Other accounts receivable and prepaid expenses	68	78
Property and equipment, net	779	1,817
Total assets of discontinued operations	3,310	6,063
Trade payables	515	702
Accrued expenses and other liabilities	143	172
Total liabilities of discontinued operations	$ 658	$ 874

GENERAL (Reverse Stock Split) (

GENERAL (Reverse Stock Split) (Details)	1 Months Ended	6 Months Ended
	Mar. 16, 2017	Jun. 30, 2017
Accounting Policies [Line Items]
Stockholders' Equity, Reverse Stock Split	On March 16, 2017, the shareholders of the Company, at an Extraordinary General Meeting of Shareholders, approved a reverse stock split and consolidation of the registered (authorized) share capital of the Company as follows: every twelve (12) Ordinary Shares with a nominal (par) value of NIS 0.6 each were consolidated into one (1) Ordinary Share with a nominal (par) value of NIS 7.2 each.	1-for-12

GENERAL (Liquidity and Capital

GENERAL (Liquidity and Capital Resources) (Details) $ / shares in Units, $ in Thousands	Sep. 28, 2017USD ($)$ / sharesshares	Aug. 09, 2017USD ($)	Aug. 03, 2017USD ($)$ / sharesshares	Mar. 16, 2017$ / shares	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)$ / shares	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)$ / shares	Dec. 31, 2016USD ($)	Aug. 03, 2017₪ / sharesshares
Share Capital [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 10.2		$ 10.2
Debt Instrument, Convertible, Conversion Price				$ 3.0544
Warrant Expiration Period				5 years
Cash and Cash Equivalents, at Carrying Value | $					$ 1,325	$ 7,821	$ 1,325	$ 7,821	$ 4,593
Estimated Offering Expenses | $			$ 2,200
Income (Loss) from Continuing Operations, Net of Tax | $					$ 1,142	$ 3,260	$ 2,904	$ 6,605	$ 13,184
Subsequent Event [Member]
Share Capital [Line Items]
Proceeds from sale of stock | $	$ 2,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	2,173,914
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.15
Sale of Stock, Consideration Received on Transaction | $		$ 2,712
Warrant Expiration Period	5 years
Debt Conversion, Converted Instrument, Shares Issued | shares	2,173,914
Subsequent Event [Member] | Convertible Debt [Member]
Share Capital [Line Items]
Debt Instrument, Term	30 years
Debt Instrument, Convertible, Conversion Price	$ 0.92
Subsequent Event [Member] | Convertible Debt [Member] | Minimum [Member]
Share Capital [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 0.20
Subsequent Event [Member] | Series A Warrant [Member]
Share Capital [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			0.50							0.50
Class A Units [Member] | Subsequent Event [Member]
Share Capital [Line Items]
Stock sold in agreement | shares			138,000
Price per unit			$ 1.40
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.50
Sale of Stock, Price Per Share | ₪ / shares										₪ 7.2
Warrant Expiration Period			5 years
Class B Units [Member] | Subsequent Event [Member]
Share Capital [Line Items]
Stock sold in agreement | shares			1,811,974
Price per unit			$ 1.39
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.01

FAIR VALUE MEASUREMENT (Narrati

FAIR VALUE MEASUREMENT (Narrative) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Warrants and Rights Outstanding	$ 2,357		$ 3,675
Derivative, Gain on Derivative	$ 1,737	$ 0

FAIR VALUE MEASUREMENT (Present

FAIR VALUE MEASUREMENT (Present Liabilities Balances Measured at Fair Value On a Recurring Basis) (Details) $ in Thousands	Jun. 30, 2017USD ($)
Level 1 [Member]
Liabilities:
Debentures and Warrants	$ 0
Total Financial liabilities	0
Level 2 [Member]
Liabilities:
Debentures and Warrants	0
Total Financial liabilities	0
Level 3 [Member]
Liabilities:
Debentures and Warrants	2,357
Total Financial liabilities	$ 2,357

FAIR VALUE MEASUREMENT (Company

FAIR VALUE MEASUREMENT (Company's Liabilities Measured At Fair Value) (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total fair value as of January 1, 2017	$ 3,675
Issuance of PIPE Debentures	1,292
Conversion of Debentures	(873)
Gain from revaluation of Debentures and Warrants	(1,737)
Total fair value as of June 30, 2017	$ 2,357

DEBENTURES AND WARRANTS (Narrat

DEBENTURES AND WARRANTS (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 16, 2017	Mar. 16, 2017	Feb. 23, 2017	Nov. 29, 2016	Nov. 23, 2016	Jun. 30, 2017	Jun. 30, 2016
Stock Issued During Period, Shares, New Issues					91,250
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 10.2
Debt Instrument, Convertible, Conversion Price	$ 3.0544	$ 3.0544
Revaluation gain losses of warrants and Debentures						$ 1,737
Stockholders' Equity, Reverse Stock Split		On March 16, 2017, the shareholders of the Company, at an Extraordinary General Meeting of Shareholders, approved a reverse stock split and consolidation of the registered (authorized) share capital of the Company as follows: every twelve (12) Ordinary Shares with a nominal (par) value of NIS 0.6 each were consolidated into one (1) Ordinary Share with a nominal (par) value of NIS 7.2 each.				1-for-12
Warrant Expiration Period	5 years
Revaluation of Liabilities [Member]
Warrants Not Settleable in Cash, Fair Value Disclosure						$ 1,682
Debt Instrument, Fair Value Disclosure						$ 675
Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues					91,250
Shares Issued, Price Per Share					$ 6
Proceeds from sale of stock				$ 3,708
Private Placements [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 10.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					833,334
Unsecured Convertible Debentures [Member] | Registered Direct Offering [Member]
Debt Instrument, Face Amount					$ 3,160
PIPE Debentures [Member]
Proceeds from Convertible Debt			$ 1,292
PIPE Debentures [Member] | Private Placements [Member]
Debt Instrument, Face Amount					$ 1,293
Debentures [Member]
Debt Instrument, Term						30 years
Debt Instrument, Convertible, Conversion Price						$ 6

DEBENTURES AND WARRANTS (fair v

DEBENTURES AND WARRANTS (fair value of the Warrants) (Details) - Warrant [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Expected dividend yield	0.00%
Warrants	$ 1,682
Minimum [Member]
Risk-free interest rate	1.16%
Expected volatility	82.98%
Expected life (in years)	7 months 17 days
Maximum [Member]
Risk-free interest rate	1.72%
Expected volatility	83.02%
Expected life (in years)	4 years 5 months 1 day

DEBENTURES AND WARRANTS (fair30

DEBENTURES AND WARRANTS (fair value of the Debentures) (Details) - Debenture [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Risk-free interest rate	1.16%
Expected volatility	88.41%
Expected life (in years)	5 months 1 day
Expected dividend yield	0.00%
Debentures	$ 675

COMMITMENTS AND CONTINGENT LI31

COMMITMENTS AND CONTINGENT LIABILITIES (Narrative) (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Long-term Purchase Commitment [Line Items]
Minimum payment upon cancellation of cancelable operating lease agreements	$ 5
Facilities [Member]
Long-term Purchase Commitment [Line Items]
Operating leases expense	218	$ 204
Vehicles [Member]
Long-term Purchase Commitment [Line Items]
Operating leases expense	18	$ 20
Land Lords [Member]
Long-term Purchase Commitment [Line Items]
Restricted Cash and Cash Equivalents	58
May 2006 License Agreement [Member]
Long-term Purchase Commitment [Line Items]
Aggregate maintenance fees/royalties	960
Maintenance fees/royalties, noncurrent	500
June 2006 License Agreement [Member]
Long-term Purchase Commitment [Line Items]
Aggregate maintenance fees/royalties	445
Maintenance fees/royalties, noncurrent	188
August 2006 License Agreement [Member]
Long-term Purchase Commitment [Line Items]
Aggregate maintenance fees/royalties	320
Maintenance fees/royalties, noncurrent	155
December 2006 License Agreement [Member]
Long-term Purchase Commitment [Line Items]
Aggregate maintenance fees/royalties	274
Maintenance fees/royalties, noncurrent	94
May 2007 License Agreement [Member]
Long-term Purchase Commitment [Line Items]
Aggregate maintenance fees/royalties	690
Maintenance fees/royalties, noncurrent	375
January 2008 License Agreement [Member]
Long-term Purchase Commitment [Line Items]
Aggregate maintenance fees/royalties	440
Maintenance fees/royalties, noncurrent	$ 250

COMMITMENTS AND CONTINGENT LI32

COMMITMENTS AND CONTINGENT LIABILITIES (Aggregate Minimum Rental Commitments Under the Non-Cancelable Rent Agreements) (Details) $ in Thousands	Jun. 30, 2017USD ($)
2,017	$ 184
2,018	283
Total	$ 467

COMMITMENTS AND CONTINGENT LI33

COMMITMENTS AND CONTINGENT LIABILITIES (future minimum lease payments ) (Details) $ in Thousands	Jun. 30, 2017USD ($)
2,017	$ 28
2,018	55
2,019	14
Total lease payments	$ 97

SHARE CAPITAL (Narrative) (Deta

SHARE CAPITAL (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	19,793
Share-based Compensation	$ 396	$ 459
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations	2,364
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number	1,019,228
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	1.14%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	2.17%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	2.33%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate	10.00%
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.56
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 3 months
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.48
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years

FINANCIAL INCOME, NET (Details)

FINANCIAL INCOME, NET (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Financial income:
Revaluation of Debentures and warrants related to share purchase agreement			$ 1,737	$ 0
Foreign currency adjustments gains, net			15	0
Total financial income			1,752	0
Financial expenses:
Foreign currency adjustments losses, net			0	9
Bank commissions			38	15
Issuance expenses of Debentures and Warrants classified as liabilities			90	0
Total financial expenses			128	24
Total financial expense (income), net	$ (229)	$ 0	$ (1,624)	$ 24